Author: COVID-19 NEWS

Links with this icon indicate that you are leaving the CDC website.

The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website’s privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.

For more information on CDC’s web notification policies, see Website Disclaimers.

IntroductionYouth and summer camps can play an important role in the lives of children, including supporting their social, emotional, and physical development. Camps provide opportunities for children to try new activities, develop relationship and social skills, and be physically active. In addition to allowing for free play and unstructured learning, many camps also incorporate educational content, which can help prevent summer learning loss. The present guidance is intended to help camp administrators operate camps while preventing the spread of COVID-19 and protecting campers, their families, staff, and communities.
Camp administrators, in collaboration with state, local, territorial, and tribal health officials, can adapt the recommendations in this guidance to meet the unique needs and circumstances of the populations served. Implementation should be guided by what is acceptable, and tailored to the needs of each community. This CDC guidance is meant to supplement—not replace—any state, local, territorial, or tribal health and safety laws, rules, and regulations with which camps must comply.
This guidance is intended for all types of youth day camps with additional guidance provided for overnight camps. Organizations that provide summer day camps on school grounds should follow this guidance. Summer learning programs on school grounds should follow CDC’s Operational Strategy for K-12 Schools through Phased Prevention. Some K-12 schools may also require the use of their COVID-19 prevention measures for organizations hosting summer day camps on school grounds.
After reviewing this guidance, camp administrators can use CDC’s Youth Programs and Camps Readiness and Planning Tool pdf icon[492 KB, 9 Pages] to protect campers, staff, and communities.
COVID-19 in Children and Adolescents
While fewer children have gotten sick with COVID-19 compared with adults during the pandemic, children can be infected with the virus that causes COVID-19, get sick with COVID-19, spread the virus to others, and have severe outcomes.1, 2, 3, 4, 5 However, children are more likely to be asymptomatic or to have mild, non-specific symptoms; they are less likely than adults to have severe illness or die.6, 7 Children with underlying medical conditions are at increased risk for severe illness from COVID-19.
Consistent use of the multiple prevention strategies described in this document can limit the spread of COVID-19 in many settings, including camps and can help camps open safely for in-person activities.8, 9, 10

Links with this icon indicate that you are leaving the CDC website.

The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website’s privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.

For more information on CDC’s web notification policies, see Website Disclaimers.

It is normal to feel sick after getting a COVID-19 vaccine.You may have a sore arm.
Put a cool, wet cloth on your sore arm.
A cool, wet cloth may make your arm feel better.
Move and use your arm.
Moving your arm may make it feel better.

You may have the chills.
You may have a fever.
Medicine may help your fever.
Drink plenty of water.

You may feel very tired.
You may need to rest.
You should feel better in a few days.

Some COVID-19 vaccines need 2 doses.
You may feel sick after dose 1.
You may feel sick after dose 2.
Make sure you get 2 doses if needed.
 
Get Help if You Feel Very Sick
Call your doctor if your arm hurts more each day.
Call your doctor if you are worried about how you feel.
Get help right away if you feel very sick.
Call 9-1-1 or the emergency department if you need help.
Tell the operator that you need help.
Tell the operator that you got a COVID-19 vaccine.
Original Guidance: Possible Side Effects After Getting a COVID-19 Vaccine | CDC

Selected Characteristics of SARS-CoV-2 Variants of Interest+
Name(Pango lineageexternal icon)a 
Spike Protein Substitutions
Name(Nextstrainexternal icon)b
First Detected
BEIexternal icon Reference Isolatec

Attributes

B.1.526
Spike:(L5F*), T95I, D253G, (S477N*), (E484K*), D614G, (A701V*)
20C/S:484K
United States (New York) – November 2020

Reduced neutralization by some, but not all EUA monoclonal antibody treatments 7,14
Reduced neutralization by convalescent and post-vaccination sera 22

B.1.526.1
Spike: D80G, Δ144, F157S, L452R, D614G, (T791I*), (T859N*), D950H
20C
United States (New York) – October 2020

Reduced neutralization by some, but not all EUA monoclonal antibody treatments 7,14
Potential reduction in neutralization by convalescent and post-vaccination sera22

B.1.525
Spike: A67V, Δ69/70, Δ144, E484K, D614G, Q677H, F888L
20A/S:484K
United Kingdom/Nigeria – December 2020

Potential reduction in neutralization by monoclonal antibody treatments 7
Potential reduction in neutralization by convalescent and post-vaccination sera 22

P.2
Spike: E484K, (F565L*), D614G, V1176F
20J
Brazil – April 2020

Potential reduction in neutralization by monoclonal antibody treatments 7,22
Reduced neutralization by post-vaccination sera 22,23

(*) = detected in some sequences but not all
+These variants share one specific mutation called D614G. This mutation was one of the first documented in the US in the initial stages of the pandemic, after having initially circulated in Europe[13]. There is evidence that variants with this mutation spread more quickly than viruses without this mutation [12].
a – Phylogenetic Assignment of Named Global Outbreak (PANGO) Lineages is software tool developed by members of the Rambaut Lab. The associated web application was developed by the Centre for Genomic Pathogen Surveillance in South Cambridgeshire and is intended to implement the dynamic nomenclature of SARS-CoV-2 lineages, known as the PANGO nomenclature.
b – Nextstrain, a collaboration between researchers in Seattle, USA and Basel, Switzerland, provides open-source tools for visualizing the genetics of outbreaks. The goal is to support public health surveillance by facilitating understanding of the spread and evolution of pathogens.
c – The Biodefense and Emerging Infections Research Resources (BEI Resources) is a NIAID-funded repository to provide reagents, tools, and information to the research community. The reference viruses proposed here facilitate the harmonization of information among all stakeholders in the COVID-19 pandemic research community. Please note that the reference viruses provided in the tables below are based on what is currently available through the BEI Resources.

Variant of Concern
A variant for which there is evidence of an increase in transmissibility, more severe disease (e.g.,  increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures.
Possible attributes of a variant of concern:
In addition to the possible attributes of a variant of interest
Evidence of impact on diagnostics, treatments, or vaccines
Widespread interference with diagnostic test targets
Evidence of substantially decreased susceptibility to one or more class of therapies
Evidence of significant decreased neutralization by antibodies generated during previous infection or vaccination
Evidence of reduced vaccine-induced protection from severe disease

Evidence of increased transmissibility
Evidence of increased disease severity
Variants of concern might require one or more appropriate public health actions, such as notification to WHO under the International Health Regulations, reporting to CDC, local or regional efforts to control spread, increased testing, or research to determine the effectiveness of vaccines and treatments against the variant. Based on the characteristics of the variant, additional considerations may include the development of new diagnostics or the modification of vaccines or treatments.
Current variants of concern in the United States that are being closely monitored and characterized by federal agencies are included in the table below. The table will be updated when a new variant of concern is identified.

Selected Characteristics of SARS-CoV-2 Variants of Concern+
Name(Pango lineageexternal icon)a
Spike Protein Substitutions

Name(Nextstrainexternal icon)b

First Detected
BEIexternal icon Reference Isolatec

Attributesd

B.1.1.7
Δ69/70,Δ144,(E484K*),(S494P*),N501Y,A570D,D614G,P681H, T716I, S982A, D1118H (K1191N*)
20I/501Y.V1
United Kingdom
NR-54000external icon

~50% increased transmission 5
Likely increased severity based on hospitalizations and case fatality rates 6
Minimal impact on neutralization by EUA monoclonal antibody treatments 7,14
Minimal impact on neutralization by convalescent and post-vaccination sera 8,9,10,11,12,13,19

P.1
L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I
20J/501Y.V3
Japan/Brazil
NR-54982external icon

Reduction in neutralization by some, but not all EUA monoclonal antibody treatments 7,14
Reduced neutralization by convalescent and post-vaccination sera 15

B.1.351
D80A, D215G, Δ241/242/243, K417N, E484K, N501Y, D614G, A701V
20H/501.V2
South Africa
NR-54009external icon

~50% increased transmission16
Reduction in neutralization by some, but not all EUA monoclonal antibody treatments 7,14
Moderate reduction in neutralization by convalescent and post-vaccination sera 8,12,18,19,20

B.1.427
L452R, D614G
20C/S:452R
United States-(California)

~20% increased transmissibility 21
Significant reduction in neutralization by some, but not all, EUA monoclonal antibody treatments 7,14
Moderate reduction in neutralization using convalescent and post-vaccination sera 21

B.1.429
S13IW152CL452RD614G
20C/S:452R
United States-(California)

~20% increased transmissibility 21
Significant reduction in neutralization by some, but not all, EUA monoclonal antibody treatments 7,14
Moderate reduction in neutralization using convalescent and post-vaccination sera 21

(*) = detected in some sequences but not all+These variants share one specific mutation called D614G. This mutation was one of the first documented in the US in the initial stages of the pandemic, after having initially circulated in Europe[13]. There is evidence that variants with this mutation spread more quickly than viruses without this mutation [12].
a – Phylogenetic Assignment of Named Global Outbreak (PANGO) Lineages is software tool developed by members of the Rambaut Lab. The associated web application was developed by the Centre for Genomic Pathogen Surveillance in South Cambridgeshire and is intended to implement the dynamic nomenclature of SARS-CoV-2 lineages, known as the PANGO nomenclature.
b – Nextstrain, a collaboration between researchers in Seattle, USA and Basel, Switzerland, provides open-source tools for visualizing the genetics of outbreaks. The goal is to support public health surveillance by facilitating understanding of the spread and evolution of pathogens.
c – The Biodefense and Emerging Infections Research Resources (BEI Resources) is a NIAID-funded repository to provide reagents, tools, and information to the research community. The reference viruses proposed here facilitate the harmonization of information among all stakeholders in the COVID-19 pandemic research community. Please note that the reference viruses provided in the tables below are based on what is currently available through the BEI resources.
d  – Attributes listed are based on data available from pseudoviruses or recombinant viruses containing combinations of substitutions characteristic of specific lineages or from reference virus isolates.
Variant of High Consequence
A variant of high consequence has clear evidence that prevention measures or medical countermeasures (MCMs) have significantly reduced effectiveness relative to previously circulating variants.
Possible attributes of a variant of high consequence:
In addition to the possible attributes of a variant of concern
Impact on Medical Countermeasures (MCM)
Demonstrated failure of diagnostics
Evidence to suggest a significant reduction in vaccine effectiveness, a disproportionately high number of vaccine breakthrough cases, or very low vaccine-induced protection against severe disease
Significantly reduced susceptibility to multiple Emergency Use Authorization (EUA) or approved therapeutics
More severe clinical disease and increased hospitalizations

A variant of high consequence would require notification to WHO under the International Health Regulations, reporting to CDC, an announcement of strategies to prevent or contain transmission, and recommendations to update treatments and vaccines.
Currently there are no SARS-CoV-2 variants that rise to the level of high consequence.

Get Ready for Your COVID-19 VaccineAsk your doctor if you should get a COVID-19 vaccine.
Ask your doctor about the medicine you take.
Ask if you should take medicine on the day of your COVID-19 vaccine.
Your doctor may tell you to change your medicine on the day of your COVID-19 vaccine.
Stay Safer Getting Your Vaccine
You must feel well to get your COVID-19 vaccine.
Wear a mask when you get your COVID-19 vaccine.
The mask will protect you.
The mask will protect others.
The mask must cover your nose.
The mask must cover your mouth.
The mask must fit under your chin.
The mask must be snug on your face.
You may have to wait in line to get your COVID-19 vaccine.
Stay 6 feet away from other people while you wait in line.
You Must Wait After You Get a COVID-19 Vaccine
People will show you where to wait after your vaccine.
People will show you where to sit after your vaccine.
Sit 6 feet away from other people while you wait.
People will watch to make sure you are safe.
People will watch you for 15 minutes or more.
People will ask you how you feel.
People will tell you when it is safe to leave.
Get the Information You Need
You will get a card.
The card tells what COVID-19 vaccine you got.
Ask if you need help reading the card.
Keep your card in case you need it later.

You may get a fact sheet.
The fact sheet tells about the COVID-19 vaccine you got.
The fact sheet may be on paper.
The fact sheet may be online.
Ask how you can get a fact sheet.
Ask if you need help reading the fact sheet.

Ask about the COVID-19 vaccine you got.
Ask how many doses you need.
Ask when you will get your doses.
Ask when you will be protected from COVID-19.

Get Ready for Your COVID-19 VaccineAsk your doctor if you should get a COVID-19 vaccine.
Ask your doctor about the medicine you take.
Ask if you should take medicine on the day of your COVID-19 vaccine.
Your doctor may tell you to change your medicine on the day of your COVID-19 vaccine.
Stay Safer Getting Your Vaccine
You must feel well to get your COVID-19 vaccine.
Wear a mask when you get your COVID-19 vaccine.
The mask will protect you.
The mask will protect others.
The mask must cover your nose.
The mask must cover your mouth.
The mask must fit under your chin.
The mask must be snug on your face.
You may have to wait in line to get your COVID-19 vaccine.
Stay 6 feet away from other people while you wait in line.
You Must Wait After You Get a COVID-19 Vaccine
People will show you where to wait after your vaccine.
People will show you where to sit after your vaccine.
Sit 6 feet away from other people while you wait.
People will watch to make sure you are safe.
People will watch you for 15 minutes or more.
People will ask you how you feel.
People will tell you when it is safe to leave.
Get the Information You Need
You will get a card.
The card tells what COVID-19 vaccine you got.
Ask if you need help reading the card.
Keep your card in case you need it later.

You may get a fact sheet.
The fact sheet tells about the COVID-19 vaccine you got.
The fact sheet may be on paper.
The fact sheet may be online.
Ask how you can get a fact sheet.
Ask if you need help reading the fact sheet.

Ask about the COVID-19 vaccine you got.
Ask how many doses you need.
Ask when you will get your doses.
Ask when you will be protected from COVID-19.

Links with this icon indicate that you are leaving the CDC website.

The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website’s privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.

For more information on CDC’s web notification policies, see Website Disclaimers.

Cruise lines that have ships operating or planning to operate in U.S. waters during the period of the No Sail Order extension
Parent Company
Cruise Line
No Sail Order Response Plan Status
Ship Name
Ship Status
Commercial Travel Allowed¥
Bahamas Paradise Cruise Line
Bahamas Paradise Cruise Line
Complete and accurate with signed acknowledgement
Grand Classica
Green
Yes
Carnival Corporation
Carnival Cruise Lines, Inc.
Complete and accurate with signed acknowledgement
Carnival Breeze
Green
Yes
Carnival Conquest
Green
Yes
Carnival Dream
Green
Yes
Carnival Ecstasy
Green
Yes
Carnival Elation
Green
Yes
Carnival Freedom
Green
Yes
Carnival Glory
Green
Yes
Carnival Horizon
Green
Yes
Carnival Liberty
Green
Yes
Carnival Mardi Gras
Provisionally Green*
No
Carnival Miracle
Green
Yes
Carnival Panorama
Green
Yes
Carnival Pride
Green
Yes
Carnival Sensation
Green
Yes
Carnival Sunrise
Green
Yes
Carnival Sunshine
Green
Yes
Carnival Vista
Green
Yes
Holland America Line
Complete and accurate with signed acknowledgement
Koningsdam
Green
Yes
Nieuw Amsterdam
Green
Yes
Nieuw Statendam
Green
Yes
Noordam
Green
Yes
Westerdam
Green
Yes
Zuiderdam
Green
Yes
Princess Cruises
Complete and accurate with signed acknowledgement
Caribbean Princess
Green
Yes
Coral Princess
Green
Yes
Emerald Princess
Green
Yes
Grand Princess
Green
Yes
Majestic Princess
Green
Yes
Royal Princess
Green
Yes
Ruby Princess
Green
Yes
Seabourn Cruise Line
Complete and accurate with signed acknowledgement
Odyssey
Green
Yes
Walt Disney Company
Disney Cruise Line
Complete and accurate with signed acknowledgement
Disney Dream
Green
Yes
Disney Fantasy
Green
Yes
MSC Cruise Management (UK) Limited
MSC Cruises
Complete and accurate with signed acknowledgement
MSC Armonia
Green
Yes
MSC Meraviglia
Green
Yes
Norwegian
Cruise Line Holdings
NorwegianCruise Line
Complete and accurate with signed acknowledgement
Norwegian Jewel
Green
Yes
Norwegian Sun
Green
Yes
Pride of America
Green
Yes
Oceania Cruises
Complete and accurate with signed acknowledgement
Oceania Regatta
Green
Yes
Royal Caribbean Group
Celebrity Cruises
Complete and accurate with signed acknowledgement
Celebrity Edge
Green
Yes
Celebrity Equinox
Green
Yes
Celebrity Solstice
Green
Yes
Celebrity Summit
Green
Yes
Royal Caribbean International
Complete and accurate with signed acknowledgement
Allure of the Seas
Green
Yes
Brilliance of the Seas
Green
Yes
Enchantment of the Seas
Green
Yes
Explorer of the Seas
Green
Yes
Freedom of the Seas
Green
Yes
Grandeur of the Seas
Green
Yes
Independence of the Seas
Green
Yes
Liberty of the Seas
Green
Yes
Mariner of the Seas
Green
Yes
Navigator of the Seas
Green
Yes
Oasis of the Seas
Green
Yes
Rhapsody of the Seas
Green
Yes
Serenade of the Seas
Green
Yes
Symphony of the Seas
Green
Yes
Vision of the Seas
Green
Yes
*Provisionally Green: Ship meets the surveillance criteria for “Green” status, but the ship has not submitted a signed attestation to CDC for crew to travel commercially.
¥Commercial Travel Allowed: Allowed for ships that are “Green” or “Orange” and have submitted a signed attestation to CDC for crew to travel commercially.
Frequently Asked Questions
Is the process for crew disembarkation under the Framework for Conditional Sailing Order different from the process during the No Sail Order period?
No, the process for crew disembarkation required during the No Sail Order period remains the same during the initial phases of the Framework for Conditional Sailing Order.
Why is CDC requiring ships to routinely test all crew members during the phases of the Framework for Conditional Sailing Order, including those on “Green” ships?
The purpose of testing during the phases of the Framework for Conditional Sailing Order is to ensure cruise ship operators have adequate health and safety protections for crew members while they build the onboard laboratory capacity needed to test crew and future passengers. There also continue to be potential exposures on board — including on “Green” ships — such as from newly embarking crew members, crew transfers, and contractors.
What steps is CDC taking to make sure ships stay in compliance with the criteria for commercial transport of crew?
CDC will review daily surveillance data provided by ships, and only those ships that do not meet “Yellow” or “Red” criteria will maintain this status.
What other changes can cruise ships make if they meet the criteria for commercial transport?
CDC is committed to helping cruise lines provide for the safety and well-being of their crew members onboard. As cruise ships are able to show they have no cases of confirmed COVID-19 or COVID-19-like illness onboard, crew members will be able to resume some of their daily interactions with fellow crew members.
Some examples of decreased restrictions on cruise ships if they meet these criteria include resuming in-person meetings, events, and social gatherings; and reopening bars, gyms, or other group settings onboard for crew member use.
What does it mean if a cruise line or cruise ship is not listed on the table above?
If a cruise line or cruise ship is not listed, it means one of the following:
CDC has not been notified that the ship is intending to operate in U.S. waters during the period of the Framework for Conditional Sailing Order, or
CDC has not completed the review of the cruise line’s plan, or
Cruise line has not returned an acknowledgement attesting that their No Sail Order response plan is complete and accurate, or
Ship has not submitted at least 4 weeks of surveillance data to CDC in accordance with the Technical Instructions.

Johnson & Johnson’s Janssen COVID-19 Vaccine: CDC and FDA have recommended a pause in the use of Johnson & Johnson’s J&J/Janssen COVID-19 Vaccine in the United States out of an abundance of caution, effective Tuesday, April 13. The Advisory Committee on Immunization Practices (ACIP) will hold its second emergency meeting to discuss J&J/Janssen COVID-19 Vaccine on April 23, 2021. People who have received the J&J/Janssen COVID-19 Vaccine within the past three weeks who develop severe headache, abdominal pain, leg pain, or shortness of breath should seek medical care right away.